Koers BioTime, Inc. Nyse
Aandelen
US09066L1052
Biotechnologie & Medisch Onderzoek
Omzet 2024 * | 12,22 mln. 11,44 mln. | Omzet 2025 * | 5,87 mln. 5,49 mln. | Marktkapitalisatie | 194 mln. 182 mln. |
---|---|---|---|---|---|
Nettowinst (verlies) 2024 * | -29 mln. -27,14 mln. | Nettowinst (verlies) 2025 * | -32 mln. -29,94 mln. | EV/omzet 2024 * | 15,9 x |
Nettoliquiditeiten 2024 * | - 0 | Nettoliquiditeiten 2025 * | - 0 | EV/omzet 2025 * | 33,1 x |
K/w-verhouding 2024 * |
-7,92
x | K/w-verhouding 2025 * |
-5,99
x | Werknemers | - |
Dividendrendement 2024 * |
-
| Dividendrendement 2025 * |
-
| Vrij verhandelbaar | 99,56% |
Recentste transcriptie over BioTime, Inc.
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Brian Culley
CEO | Chief Executive Officer | 53 | 17-09-18 |
Jill Howe
DFI | Director of Finance/CFO | 48 | 14-11-22 |
Chief Operating Officer | - | 01-01-10 |
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Neal Bradsher
BRD | Director/Board Member | 58 | 01-07-09 |
Brian Culley
CEO | Chief Executive Officer | 53 | 17-09-18 |
Deborah Andrews
BRD | Director/Board Member | 66 | 11-04-14 |
Vaira. 1 jan. | Kapi. | |
---|---|---|
+21,85% | 46,44 mld. | |
+37,63% | 39,1 mld. | |
-8,05% | 38,76 mld. | |
+29,04% | 31,24 mld. | |
-13,75% | 25,8 mld. | |
+10,65% | 25,9 mld. | |
+38,43% | 13,12 mld. | |
-6,92% | 11,32 mld. | |
-12,29% | 10,68 mld. |